Introduction
============

Alzheimer\'s disease (AD), a progressive neurodegenerative disease, is the most common cause of dementia in the elderly, affecting approximately 5.7 million Americans in 2018 [@B1]. In recent decades, AD biomarkers have attracted tremendous attention in clinical diagnosis because they precede clinical symptoms by 10-15 years. Tau and beta-amyloid (Aβ), reflecting the key neuropathological hallmarks of AD pathology, are the most intensively studied molecular biomarkers. Compared to samples from healthy controls, cerebrospinal fluid (CSF) from AD patients shows a decreased level of Aβ~42~ and increased levels of total tau (t-tau) and tau phosphorylated at Thr~181~ (p-tau~181~). Currently, surface plasmon resonance, enzyme-linked immunosorbent assay (ELISA), and electrochemical methods have been reported for the detection of AD biomarkers [@B2]-[@B12]. However, they still have limitations in the form of moderate sensitivity, long incubation time, alteration of antibody or enzyme activity due to prelabeling with fluorophores, and, most importantly, a lack of multiplexing. A change in the level of any particular protein is not exclusive to AD. For example, decreases in Aβ~42~ can be found in other neurodegenerative diseases, including Parkinson\'s disease (PD), frontotemporal dementia (FTD), vascular dementia (VaD) and Lewy body dementia (LBD) [@B13]. Hence, the combined assessment of CSF Aβ~42~, t-tau and p-tau~181~ improves diagnostic accuracy, increasing demand for a simultaneous detection tool [@B14]-[@B16].

Simultaneous detection of a series of clinically relevant protein biomarkers is indispensable for clinical applications. However, the levels of different biomarkers may cover an expansive range; a biosensor for such markers requires not only high sensitivity but also a broad detection range [@B17]. For instance, the cut-off levels of Aβ~42~, t-tau and p-tau~181~ are 530 pg/mL (117.4 pM), 350 pg/mL (7.6 pM) and 80 pg/mL (1.7 pM) [@B18]. Hence, although many biosensors for specific biomarkers have been reported, the development of multiplex detection of AD biomarkers remains limited. Recently, several nanomaterial-based multiplex detection methods for AD biomarkers have been developed [@B19]-[@B22]. However, they provide qualitative rather than quantitative measurements, and their sensitivity is not yet adequate.

In response to the problem of sensitivity, an aptamer-based assay has been rapidly developed in the last few years [@B23]. Aptamers are single-stranded nucleic acids obtained through systematic evolution of ligands by exponential enrichment (SELEX), which involves multiple rounds of iterative selection and amplification of bound sequences [@B24]. The random sequences will fold into 3D structures with binding sites complementary to target proteins. To date, thousands of aptamers binding to specific targets including small organic molecules, small metal ions, proteins, peptides, surface proteins and other molecules on live cells, and live cells themselves, as well as bacteria and viruses, have been developed [@B25]-[@B28]. Aptamers have numerous advantages over antibodies, including higher or comparable target affinity, higher stability, and lower batch-to-batch variation, and lower manufacturing and shipping costs; most importantly, other technologies involving nucleic acid-based systems, such as DNA nanotechnology, DNA computing and amplification techniques, are also applicable to aptamers [@B29], [@B30].

We have previously reported multiplex biosensors based on different emission wavelengths of fluorophores on single magnetic immunocomplexes [@B31], [@B32]. In short, fluorescence images were first captured by a total internal reflection fluorescence microscopy electron-multiplying charge-coupled device (TIRFM-EMCCD) imaging system coupled with a transmission grating, and the emission spectra were resolved from the first-order images. The identities of the single light spots were correlated with the emission peak of the respective labeling fluorophores of the magnetic immunocomplexes.

Herein, to further improve on the previous detection assay, we report a direct and ultrasensitive multiplex assay using a hybrid antibody-aptamer sandwich immunoassay. Briefly, the target proteins are captured by the capture antibody-conjugated magnetic nanoplatform and aptamer, and the signal is further amplified by a pair of amplification probes. A tailor-made fluorophore, namely, SPOH, then labels the magnetic hybrids for visualization under a fluorescence imaging system. This assay is capable of achieving higher sensitivity than the antibody-antibody system in quantifying target analytes in both CSF and serum samples. Aβ~42~ and tau~441~ can be simultaneously recognized and detected using two magnetic probes with different morphologies. The results obtained by single and multiplex approaches were comparable to one another and were validated using ELISA.

Methods
=======

Chemicals and reagents
----------------------

A Tris-EDTA conjugation buffer (TE) was prepared by mixing 20 mM pH 8.0 Tris-HCl (Invitrogen) with 1 mM EDTA (Sigma) in distilled water, while Tris-NaCl-EDTA reaction buffer (TNE) was prepared by mixing 20 mM pH 8.0 Tris-HCl with 1 mM EDTA and 250 mM sodium chloride (Sigma) in distilled water. The pH of each buffer was adjusted to pH 7.4 with 1 M HCl. The buffer solutions were filtered through a 0.22 µm nylon membrane filter and autoclaved prior to use. The previously reported aptamers for both Aβ and tau species [@B33]-[@B35] were purchased from Invitrogen, along with the amplification probes am1 and am2. The aptamer for Aβ~42~ (Aβ P) was as follows: 5′-AGT CTA GGA TTC GGC GTG GGT TAA TTT TTT GCT GCC TGT GGT GTT GGG GCG GGT GCG-3′. The aptamer for tau~441~ and p-tau~181~ (tau P) was as follows: 5′-AGT CTA GGA TTC GGC GTG GGT TAA TTT TTT GCG GAG CGT GGC AGG-3′. The sequence of Am1 was as follows: 5′-TTT TTT TTA ACC CAC GCC GAA TCC TAG ACT CAA AGT AGT CTA GGA TTC GGC GTG-3′. The sequence of Am2 was as follows: 5′-AGT CTA GGA TTC GGC GTG GGT TAA CAC GCC GAA TCC TAG ACT ACT TTG TTT TTT-3′. All oligonucleotides were suspended in DEPC-treated water (Ambion) and diluted to appropriate concentrations with TNE buffer. The melting temperatures were predicted based on the nearest neighbor method. The following commercially available antibodies were purchased and used without further purification: 12F4 for Aβ~42~ (SIG-39142, Covance), BT2 for tau~441~ (MN1010, Thermo Scientific) and AT270 for p-tau~181~ (MN1050, Thermo Scientific). Human CSF and serum were purchased from PrecisionMed. Aβ~42~ and tau~441~ were purchased from rPeptide, and p-tau181 was purchased from Invitrogen.

Synthesis of SPOH
-----------------

For the synthesis of (E)-1-(2-hydroxyethyl)-4-(2-(9-(2-(2-methoxyethoxy)ethyl)-9H-carbazol-3-yl)vinyl)pyridin-1-ium chloride (SPOH), a solution of pyridinium salt **1** (0.13 g, 0.75 mmol), 9-(2-(2-methoxyethoxy)ethyl)-9H-carbazole-3-carbaldehyde (0.27 g, 0.9 mmol) and piperidine (0.1 mL) in ethanol (30 mL) was heated to reflux overnight. After cooling to room temperature, the organic solvent was removed by rotary evaporation. The residue was purified by recrystallization from methanol, producing SPOH (0.18 g) as a pale red solid at a 53% yield. ^1^H NMR (400 MHz, DMSO-*d~6~*) δ 8.88 (d, *J* = 6.8 Hz, 2H), 8.55 (s, 1H), 8.19 (m, 4H), 7.84 (d, *J* = 8 Hz, 1H), 7.65 (m, 2H), 7.49 (m, 2H), 7.25 (t, *J* = 7.2 Hz, 1H), 5.66 (s, 1H), 4.57 (m, 4H), 3.79 (m, 4H), 3.43 (m, 2H), 3.27 (m, 2H), 3.08 (s, 3H). ^13^C NMR (100 MHz, DMSO-*d~6~*) δ 153.4, 144.4, 142.4, 141.7, 140.8, 126.4, 126.3, 126.2, 122.7, 122.6, 122.1, 121.1, 120.3, 120.0, 119.7, 110.4, 110.2, 71.2, 69.8, 68.8, 61.6, 600.1, 58.1, 42.8. HRMS (MALDI-TOF) m/z calculated for C~26~H~29~N~2~O~3~ 417.2172 found 417.2184 \[M^+^\].

Coverslip pretreatment and preparation of the flow cell
-------------------------------------------------------

All the coverslips were prewashed prior to use. Briefly, No. 1 22-mm × 22-mm glass slides (Gold Seal, Electron Microscopy System) were successively sonicated for 10 min in household detergent, acetone, ethanol and distilled water. The slides were then soaked in piranha solution (H~2~SO~4~:H~2~O~2~) (v/v 3:1) for 30 min and sonicated for 30 min, then sonicated again in a solution of HCl:H~2~O:H~2~O~2~ (v/v 1:1:1) at 60 °C for 30 min and soaked in piranha solution for another 30 min, followed by sonication for 30 min. Between steps, all the slides were rinsed thoroughly with filtered H~2~O. The slides were stored in filtered water and blow-dried with nitrogen gas before use. A flow cell was prepared by combining the pretreated coverslips and the lower 22 mm × 32 mm coverslips with double-sided adhesive tape with a channel width of approximately 3 mm each.

Fabrication of iron oxide nanoparticles
---------------------------------------

The monodisperse iron oxide nanoparticles were fabricated by a solvothermal method as previously reported [@B36], [@B37]. Briefly, 1.5 g of FeCl~3~ was dissolved in 20 mL of ethylene glycol:diethylene glycol (v/v 1:1), followed by the addition of 1.5 g of anhydrous sodium acetate and 1 g of polyethylene glycol (MW 600) with vigorous stirring. The solution was then transferred into a 25 mL Teflon-lined stainless steel autoclave. The autoclave was heated to 210 °C for 2 h and then cooled to room temperature. The black particles were washed repeatedly with ethanol and filtered H~2~O.

Application of a silica coating to the iron oxide nanoparticles
---------------------------------------------------------------

The particles were sonicated with 0.1 M HCl for 10 min and rinsed thoroughly with filtered H~2~O. A silica coating was applied by adding the nanoparticles to a mixture of EtOH:H~2~O:NH~3~ (v/v 80:20:1) and then adding an ethanolic solution of TEOS (500 µL of TEOS in 5 mL of ethanol) under sonication. The resulting particles were washed twice with ethanol and H~2~O and resuspended in ethanol.

Fabrication of magnetic Janus rods
----------------------------------

The iron oxide nanoparticles were coated with a thin layer of silica prior to the synthesis of Janus rods. Briefly, the nanoparticles were sonicated with 0.1 M HCl for 10 min and washed thoroughly with filtered H~2~O. The silica coating was applied by adding an ethanolic solution of TEOS (100 µL in 1.5 mL of EtOH) to a mixture of 48.4 mL of 32% NH~4~OH:H~2~O:EtOH (v/v/v 1:8:13) and 20 mg of washed magnetic nanoparticles under sonication. The reaction was completed in 3 h. The formed particles were centrifuged to discard excess reactants, washed with ethanol and water and redispersed in 30 mL of ethanol. The Janus rods were prepared via a wet-chemical method. Briefly, PVP (3 g) was dissolved in 1-hexanol (30 mL) by sonication for 2 h. Then, a mixture of 3 mL of the previously prepared nanoparticles, 840 µL of H~2~O, 200 µL of aqueous solution of 0.18 M sodium citrate, 675 µL of 32% NH~4~OH and 300 µL of TEOS were added to the mixture. After being gently shaken for 3 min, the solution was left undisturbed in an oven at 50 °C for 24 h. The product was centrifuged at 1500 ×*g* for 1 h, and the supernatant was discarded. The product was redispersed in ethanol, and the centrifugation was repeated at 1500 ×*g* for 15 min, 2 times with ethanol, 2 times with water and again with ethanol. Finally, the product was magnetically separated and washed with ethanol and redispersed in 1 mL of ethanol.

Preparation of the nanoprobes
-----------------------------

The nanoprobes were prepared by conjugating the capture antibody with the nanoparticles. The nanoparticles were first amino-functionalized by APTES, and then conjugated with the capture antibody using the cross-linking reagent glutaraldehyde. Briefly, the nanoparticles were added to an ethanolic solution of APTES (APTES:particles, w/w 100:1) and stirred at 70 °C for 24 h. The resulting particles were washed with ethanol twice, then dispersed in 5% glutaraldehyde and stirred at room temperature for 1.5 h. Subsequently, the particles were washed twice with Tris-EDTA buffer (20 mM Tris-HCl, 1 mM EDTA, pH 7.4) (TE) and dispersed in TE solution. Then, an excess amount of capture antibody was incubated with the resulting particles at room temperature for 1.5 h. The antibody-conjugated nanoparticles were washed twice with Tris-NaCl-EDTA buffer (20 mM Tris-HCl, 250 mM NaCl, 1 mM EDTA, pH 7.4) (TNE) and redispersed in TNE solution.

Optimization of the working conditions of the detection assay
-------------------------------------------------------------

To determine the optimal amount of the nanoprobes, we incubated different concentrations of the nanoprobes (1, 10, 100, and 1000 µg/mL) with 1 pM Aβ~42~ and 20 pM Aβ P, am~1~ and am~2~, at 72 °C for 1.5 h and labeled them with 100 µM SPOH. To determine the optimal reaction time, we incubated 1 pM Aβ~42~ with the nanoprobes along with 20 pM Aβ P, am~1~ and am~2~ for 30, 60 and 90 min, respectively, and labeled the probes with 100 µM SPOH. In the interest of ensuring maximum coverage of the nanoprobes, nanoprobes, prepared by 4-, 40-, 80- and 400-fold dilutions of the stock antibody solution were labeled with 100 µM SPOH. The magnetic nanocomposites (MNCs) prepared by incubating the 1 pM Aβ~42~ with Aβ P, am~1~ and am~2~ were labeled with 1, 10, 100 and 250 µM of SPOH to determine the optimal concentration of SPOH. All of the abovementioned resulting MNCs were injected into the flow cell for imaging.

Quantification of the target protein
------------------------------------

The calibration curve of the detection assay was constructed by correlating the average net intensity of 50 individual MNCs at each concentration of spiked protein biomarkers. Aβ~42~, tau~441~ and p-tau~181~ at different concentrations (0-1000 fM) were incubated with optimal amount of nanoprobes and 20 pM detection probe (Aβ P, Tau P), am~1~ and am~2~, respectively, at 72 °C for 1.5 h. The resulting MNCs were labeled with 100 µM SPOH and then flowed into the channel of the flow cell. Fluorescence images of the MNCs were captured by total internal reflection fluorescence microscopy (TIRFM) with an excitation wavelength of 488 nm.

Simultaneous quantification of the target proteins with 10% glycerol
--------------------------------------------------------------------

To explore the feasibility of detection with a commercial fluorimeter, we incubated different concentrations of Aβ~42~ (0-1000 fM) with the optimal amounts of nanoprobes, Aβ P, am~1~ and am~2~ under the optimal conditions in a 10% glycerol-TNE solution at 72 °C for 1.5 h. The resultant MNCs were labeled with 100 μM SPOH, and the fluorescence spectra of the MNCs were recorded with a fluorescence spectrophotometer (PTI QM-4/2005).

Selectivity of the detection assay
----------------------------------

To evaluate the selectivity of the detection assay, we prepared four samples: a mixture of Aβ~42~ nanoprobes and 20 pM Aβ P, am~1~ and am~2~, incubated with (i) 0 fM Aβ~42~, (ii) 250 fM Aβ~40~, (iii) 250 fM Aβ~42~, or (iv) a mixture of 250 fM Aβ~40~ and 250 fM Aβ~42~. The MNCs were then labeled with 100 µM SPOH and observed by TIRFM.

ELISA
-----

INNOTEST β-Amyloid~1-42~, Phospho-tau(181P) and hTau Ag were purchased from Fujirebio (Belgium). The detection of Aβ~42~, t-tau and p-tau~181~ was performed in duplicate following the manufacturer\'s assay protocol. For the quantification of Aβ~42~, 25 μL of Aβ~42~ standards and CSF samples were added to the capture antibody-coated microwells, followed by 75 μL of biotinylated detection antibody. The mixtures were then incubated at room temperature for 1 h. The wells were emptied and washed five times with 1x wash solution. Then, 100 μL of peroxidase-labeled streptavidin was added to the wells and incubated at room temperature for 30 min. The wells were emptied and washed five times with 1x wash solution. Next, 100 μL of the TMB substrate was added to the wells and incubated in the dark at room temperature for 30 min. Finally, 50 μL of stop solution was added to each well, and the plate was shaken carefully for 1 min. The absorbance at 450 nm was recorded by a Benchmark Plus Microplate Reader. The quantification of t-tau was performed as follows: 25 μL of t-tau standards and CSF sample were added to the capture antibody-coated microwells, followed by 75 μL of biotinylated detection antibody. The mixtures were then incubated at room temperature for 16 h. The wells were emptied and washed five times with 1x wash solution. Then, 100 μL of peroxidase-labeled streptavidin was added to the wells and incubated at room temperature for 30 min. The wells were emptied and washed five times with 1x wash solution. Next, 100 μL of the TMB substrate was added to the wells and incubated in the dark at room temperature for 30 min. Finally, 50 μL of stop solution was added to each well, and the plate was shaken carefully for 1 min. The absorbance at 450 nm was recorded by a Benchmark Plus Microplate Reader. The level of p-tau was determined by the following approaches. In brief, 75 μL of t-tau standards and CSF sample were added to the capture antibody-coated microwells, followed by 25 μL of biotinylated detection antibody. The mixtures were then incubated at 4 °C for 16 h. The wells were emptied and washed five times with 1x wash solution. Then, 100 μL of peroxidase-labeled streptavidin was added to the wells and incubated at room temperature for 30 min. The wells were emptied and washed five times with 1x wash solution. Next, 100 μL of the TMB substrate was added to the wells and incubated in the dark at room temperature for 30 min. Finally, 50 μL of stop solution was added to each well, and the plate was shaken carefully for 1 min. The absorbance at 450 nm was recorded by a Benchmark Plus Microplate Reader.

Gel electrophoresis
-------------------

To validate the formation of the hybrids between the aptamer probe and amplification probes, we prepared different samples including (i) a mixture of am~1~ and am~2~, (ii) Aβ P, a mixture of Aβ P, am1 and am2 in the (iii) absence and (iv) presence of Aβ~42~, (v) tau P, and a mixture of tau P, am1 and am2 in the (vi) absence and (vii) presence of tau~441~. In the gel electrophoresis assay, a sample containing 10 μL of each reaction sample and 2 μL of 6× loading buffer was subjected to an 8% nondenaturing polyacrylamide gel in 1× Tris-borate-EDTA buffer (TBE). After running at 180 V for 10 min, the gels were run at a constant voltage of 80 V for 2-3 h. After SYBR Green I staining, the gels were scanned using an Image Master VDS-CL (Amersham Biosciences).

Data analysis
-------------

Briefly, fluorescence images of 20 consecutive frames were acquired at different positions from the channel using the WinSpec/32 software provided by Princeton Instruments. All images were analyzed in ImageJ. The fluorescence signal from a single MNC was obtained by measuring the fluorescence intensity of 50 individual MNCs randomly. Net intensity = 1×1 square pixel of the MNCs - 1×1 square pixel of the corresponding background on the image. The average net intensity was obtained by averaging the net intensities of 50 individual MNCs.

Simultaneous detection of protein biomarkers
--------------------------------------------

To achieve simultaneous detection, we prepared probes targeting Aβ~42~ and tau~441~ by conjugating magnetic nanorods and magnetic nanoparticles, respectively, with their corresponding capture antibodies. A mixture of these two probes was incubated with the target analytes, aptamers and amplification probes, followed by labeling with SPOH. The dye-labeled magnetic nanocomposites were then infused into the in-house flow cell. The fluorescence images were then acquired with a TIRFM-EMCCD imaging system.

Results and discussion
======================

Detection scheme
----------------

A schematic illustration of the detection assay in the single approach is shown in **Figure [1](#F1){ref-type="fig"}**. The magnetic nanocomposites (MNCs) formed by the capture antibody-modified magnetic nanoparticles (MNPs-Ab), target proteins, aptamer and amplifier were labeled with the tailor-made fluorophore SPOH, which has absorption and emission maxima at 420 nm and 573 nm, respectively (**Figure [S1](#SM0){ref-type="supplementary-material"}A**). The labeled MNCs were then placed into a flow cell prepared with glass coverslips and driven from the bulk solution towards the cover slide/solution interface for TIRFM imaging. Fluorescence images of the MNCs were captured with a TIRFM-EMCCD system using a 488 nm cyan excitation laser.

The silica-coated iron oxide nanoparticles were prepared in two steps as previously reported: solvothermal synthesis of iron oxide nanoparticles and coating with silica by the sol-gel method [@B38]. TEM imaging demonstrated that the nanoparticles were spherical with an average diameter of 277 ± 8.8 nm (**Figure [S2](#SM0){ref-type="supplementary-material"}**). The positions and relative intensities of all diffraction peaks shown in the X-ray diffraction (XRD) spectra were ascribed to magnetite, Fe~3~O~4~ (**Figure [S1](#SM0){ref-type="supplementary-material"}B**). The powder sample was further analyzed by X-ray photoelectron spectroscopy (XPS), and the Fe2p~3/2~ peak and Fe2p~1/2~ peak were observed. The Fe2p~3/2~ peak is narrower and has a larger area than the Fe2p~1/2~ peak, which is in close agreement with the previous literature (**Figure [S1](#SM0){ref-type="supplementary-material"}C**) [@B39]. The resulting magnetic nanoparticles were well dispersed in solution and responded to a small bar magnet instantly.

First, gel electrophoresis was performed to validate the successful formation of wire-shaped DNA nanodevices (**Figure [S3](#SM0){ref-type="supplementary-material"}**). Lane 1, corresponding to the mixture of am1 and am2, exhibited no amplification event. Lane 3 showed ladder-shaped bands when Aβ P was present in the mixed solution of am~1~ and am~2~, indicating successful formation of DNA nanodevices with different molecular weights. The introduction of target Aβ~42~ had no effect on the formation of DNA nanodevices. Similarly, **Figure [S2](#SM0){ref-type="supplementary-material"}** also demonstrated the tau P-triggered cascade hybridization reaction between am1 and am2 in the presence (lane 7) or absence (lane 6) of target tau441.

The sensitivity of the detection assay is heavily dependent on the fluorescence response of the turn-on fluorophore. In this assay, the signal output is induced by the amplified DNA assembly, which is fluorescently labeled. Here, compared with the previously employed fluorophores, SLAce and SIM, SPOH demonstrates the highest turn-on fluorescence enhancement (approximately 15-fold) once it binds to typical ds-DNA, λ-DNA. (**Figure [S4](#SM0){ref-type="supplementary-material"}**). This result suggests that SPOH would provide improved signal output for aptamer-based detection.

To achieve higher detection efficiency, we then investigated the effect of the dose of magnetic probes on the resulting signal. Although a higher concentration of the magnetic nanoparticle in the detection assay increases the capturing efficiency, the target proteins might also distribute themselves among individual magnetic nanoparticles, averaging out the fluorescence signal of each individual. An optimal concentration of the magnetic nanoparticles must attain a balance between capturing efficiency and signal output. Hence, the sensitivity of the assay can ultimately be improved. **Figure [2](#F2){ref-type="fig"}A** illustrates that the fluorescence signals detected with 0.1 and 1 mg/mL of magnetic nanoparticles were higher than those of 2 and 10 mg/mL, which agreed well with our anticipation that an extremely high concentration of the nanoparticle would average out the resulting fluorescence signal. To achieve highly sensitive detection of the target proteins without limiting the probability of the target molecules reaching the capture probe, we used 1 mg/mL of the magnetic nanoparticle for the rest of the experiment. To further improve the performance of the detection assay with regard to the concentration of the fluorophores, we examined the relationship between the average net intensity and the concentration of SPOH; the results are shown in **Figure [2](#F2){ref-type="fig"}B**. The net intensity of the MNCs was highly dependent on the concentration of SPOH used between 1 and 100 µM. Beyond 100 µM, the MNCs were saturated with the dye. This result suggests that the optimal concentration of SPOH is 100 µM. As shown in **Figure [2](#F2){ref-type="fig"}C**, the fluorescence signal of the nanoparticles is maximal when they are prepared by 0.8 nM of the capture antibody, implying that the capture antibody surface coverage on the nanoparticle was saturated. To investigate the optimal reaction time for the interactions of the target protein, capture antibody, aptamer and amplifier, we incubated the MNCs at 72 °C for 30, 60, 90 and 120 min. As depicted in **Figure [2](#F2){ref-type="fig"}D**, the net intensity was at its highest when the MNCs were incubated for 90 min and decreased afterwards, which implies that prolonged incubation may alter the conformation of the proteins or nucleic acids, thus affecting the binding of the probes and targets.

Calibration curve
-----------------

The sensitivity of the detection assay for the quantification of protein biomarkers was investigated by varying the concentration of the target proteins. Under the optimal conditions, a calibration curve of the average net intensity as a function of the concentration of the target proteins was constructed (**Figure [3](#F3){ref-type="fig"}A**). In brief, target proteins of different concentrations ranging from 0 to 1000 fM were incubated with 1 mg/mL MNPs-Ab and 20 pM of detection probe and amplifiers at 72 °C followed by labeling with SPOH. By measuring the fluorescence intensity of 50 individual MNCs as a function of the target protein concentration, as shown in **Figure [3](#F3){ref-type="fig"}A**, we generated a linear curve with good coefficients of determination, R^2^ = 0.9923, 0.9996 and 0.9981 for Aβ~42~, tau~441~ and p-tau~181,~ respectively. The limits of detection for Aβ~42~, tau~441~ and p-tau~181~ were 8.4 fM (38 fg/mL), 4.3 fM (197 fg/mL) and 3.6 fM (165 fg/mL), respectively. With regard to the cut-off values of Aβ~42~, tau~441~ and p-tau~181~ (530, 350 and 80 pg/mL, respectively), the detection assay was able to quantify the target proteins directly from the untreated samples for clinical diagnosis. Compared with the previously reported methods, as summarized in **Table [S1](#SM0){ref-type="supplementary-material"}**, this newly developed assay was able to quantify the target proteins within 1.5 h with increased sensitivity. Moreover, the limits of detection for Aβ~42~, tau~441~ and p-tau~181~ were 23 fM (104 fg/mL), 14 fM (643 fg/mL) and 34 fM (1.56 pg/mL), respectively; thus, this assay enhanced sensitivity by 2- to 9-fold at one-third of the cost compared with our previously reported method [@B32].

Specificity
-----------

The accuracy of the detection assay is significantly affected by the specificity of the MNPs-Ab. To assess the specificity of the assay, we incubated the probes for both Aβ~42~ and p-tau~181~ with their corresponding target proteins, homologous proteins Aβ~40~ and tau, and a mixture of target proteins and homologous proteins under optimal conditions. The differences in average net intensity caused by the presence of homologous proteins were 1.0% and 0.9% for Aβ, and 4.8% and 0.5% for tau (**Figure [4](#F4){ref-type="fig"}**). These differences were calculated as (difference in signal between sample and blank)/blank × 100% or (difference in signal between mixtures and target)/signal from target × 100%. There was a negligible change in the signal in the presence of homologous proteins, implying that such MNP-Abs are highly specific and can be differentiated from their homologous peptides.

Detection of target proteins in real samples
--------------------------------------------

To demonstrate the feasibility of the assay for clinical diagnosis, the newly developed assay was applied to detect and quantify the target proteins in CSF and serum samples directly from healthy donors (donors \#8523 and \#7090093) and AD patients (donor \#8075) by external calibration. As shown in **Table [1](#T1){ref-type="table"}**, the CSF sample donated by an AD patient has a reduced concentration of Aβ~42~ and increased concentrations of tau~441~ and p-tau~181~, which supports a previous study showing that the level of Aβ~42~ decreases and those of tau~441~ and p-tau~181~ increase during the development of AD [@B40]. As illustrated in **Figure [5](#F5){ref-type="fig"}**, all of the results agreed very well with those determined using a commercially available ELISA kit. It is important to note that the expression profiles of Aβ~42~, tau~441~ and p-tau~181~ in the serum samples were different from those in the CSF samples. As demonstrated in **Figure [S5](#SM0){ref-type="supplementary-material"}**, the content of Aβ~42~ in serum samples is much lower than that in CSF samples, while tau~441~ and p-tau~181~ levels in both serum samples from AD patients and elderly donors are much lower than those in young controls.

Direct quantification of the biomarkers using a commercial fluorimeter
----------------------------------------------------------------------

Having created an ultrasensitive detection assay, we sought to increase its throughput; thus, the feasibility of using a less sensitive commercially available spectrofluorimeter was explored. To further enhance the signal output of the SPOH fluorophore, we added a 10% glycerol solution to the final MNC solution. As illustrated in **Figure [3](#F3){ref-type="fig"}B**, a linear response with a limit of detection of 143 fM for Aβ~42~ was achieved using SPOH as the reporter for the MNCs. Hence, the detection assay was able to quantify the biomarkers in a general laboratory setting. The detection assay using the spectrofluorimeter was then applied to quantify the biomarkers in human CSF samples; the contents of Aβ~42~ were 536±48, 776±6 and 288±15 pg/mL for donors \#8075, \#7090093 and \#8523, respectively, which was consistent with the results obtained using the ELISA kit (donors \#8075, \#7090093, and \#8523: 564±30, 713±12 and 265±10 pg/mL, respectively).

Simultaneous detection of protein biomarkers
--------------------------------------------

Multiplex detection not only has the ability to improve the throughput of analysis but also minimizes sample consumption and analysis time. We employed two different nanoparticle morphologies, i.e., a rod shape and a spherical shape, in the assay. Different antibodies targeting different protein biomarkers were conjugated with the separate nanoplatforms (i.e., antibody for Aβ~42~ on the nanorods and tau~441~ antibody on the nanoparticles). These two probes were then incubated with both target proteins, Aβ P, tau P, am1 and am2, followed by fluorescent labeling. The fluorescently labeled hybrids were then visualized using TIRFM. The shape of the nanoplatforms visualized under TIRFM indicated the identity of the target proteins, in which nanorods indicated Aβ~42~ and round particles indicated tau~441~. Their respective fluorescence intensities indicated the quantities of the target protein molecules. Hence, direct and simultaneous quantification of AD biomarkers was successfully achieved by measuring the fluorescence intensity of each type of nanoplatform, as shown in **Figure [6](#F6){ref-type="fig"}A**. This multiplex approach is attractive because it requires only one excitation light source and one fluorophore compound. As illustrated in **Figure [6](#F6){ref-type="fig"}B-C**, a calibration curve of the average net intensity as a function of the concentration of the target proteins was established. Limits of detection of 15 and 4 fM with R~2~ = 0.9987 and 0.9989 were achieved for Aβ~42~ (rod-shaped) and tau~441~ (spherical), respectively. We further applied this simultaneous approach to quantify the biomarkers in human CSF samples. The Aβ~42~ levels in donors \#8075, \#7090093, and \#8523 were 531±5, 740±15 and 267±2 pg/mL, respectively, while the levels of tau~441~ in these three donors were 318±15, 139±1 and 235±3 pg/mL, respectively. The results obtained by this approach were comparable to those obtained by ELISA, with relative percentage differences ranging from 0.3% to 6.2%.

Conclusions
===========

In summary, we have developed a direct, inexpensive and highly sensitive aptamer-based multiplex detection assay for the quantification of AD protein biomarkers by employing a tailor-made turn-on fluorophore, SPOH, along with TIRFM. With the use of aptamers and a DNA-based amplification strategy, the limit of detection could be lowered by one order of magnitude, reaching 8.4, 4.3 and 3.6 fM for Aβ~42~, tau~441~ and p-tau~181~, respectively. This newly developed detection assay is simple and does not require prelabeling of the antibody or aptamer, and it can also differentiate the protein isoform Aβ~42~ from Aβ~40~ and the phosphorylated form from the nonphosphorylated form of tau proteins. Furthermore, it was successfully applied to quantify the target proteins in human CSF and serum samples, and the results were in close agreement with those obtained through ELISA. Furthermore, this novel assay is one-third the cost and affords 2- to 9-fold enhancement of sensitivity compared to the previously reported antibody-antibody method. Remarkably, different target proteins can be simultaneously detected with ease by taking advantage of the different shapes of the magnetic nanoplatforms assembled. Thus, this advanced and intelligently engineered assay has great potential as a practical tool for the prognosis and diagnosis of AD.
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Aβ~42~

:   amyloid beta 1-42

Aβ P

:   detection probe for amyloid beta 1-42

AD

:   Alzheimer\'s disease

am1

:   amplification probe 1

am2

:   amplification probe 2

APTES

:   (3-aminopropyl)triethoxysilane

CSF

:   cerebrospinal fluid

ds-DNA

:   double-stranded DNA

EDTA

:   ethylenediaminetetraacetic acid

ELISA

:   enzyme-linked immunosorbent assay

MNCs

:   magnetic nanocomposites

MNPs-Ab

:   capture antibody-modified magnetic nanoparticles

p-tau~181~

:   tau phosphorylated at threonine 181

PVP

:   polyvinylpyrrolidone

SELEX

:   systematic evolution of ligands by exponential enrichment

SEM

:   scanning electron microscopy

TIRFM-EMCCD

:   total internal reflection fluorescence microscopy electron-multiplying charge-coupled device

t-tau

:   total tau

tau P

:   detection probe for tau

TBE

:   tris-borate-ethylenediaminetetraacetic acid buffer

TE

:   tris-ethylenediaminetetraacetic acid conjugation buffer

TEM

:   transmission electron microscopy

TEOS

:   tetraethoxysilane

TMB

:   3,3′,5,5′-tetramethylbenzidine

TNE

:   tris-sodium chloride-ethylenediaminetetraacetic acid buffer reaction buffer

![Synthesis of SPOH. Reagents and conditions: a) MeCN, ClCH~2~CH~2~OH, reflux; b) **1**, piperidine, EtOH, reflux.](thnov09p2939g001){#SC1}

![Schematic illustration of the detection assay for the direct quantification of target AD protein biomarkers. Scale bar of the TIRFM image = 10 μm.](thnov09p2939g002){#F1}

![Optimization of **(A)** concentration of capture antibody-conjugated probes, **(B)** concentration of fluorophore (SPOH), **(C)** concentration of capture antibody and **(D)** reaction time. Error bars, standard error of the mean; n = 3. Average net intensity = ((1×1 square pixel of 50 individual MNCs) - (1×1 square pixel of 50 individual background areas on the TIRFM images)) / 50.](thnov09p2939g003){#F2}

![**(A)** Calibration curve for the quantification of monomeric Aβ~42~, tau~441~ and p-tau~181~ using SPOH. The nanoprobes were incubated with different concentrations of target under optimal conditions. Error bars, standard error of the mean; n = 3. Average net intensity = ((1×1 square pixel of 50 individual MNCs) - (1×1 square pixel of 50 individual background area on the TIRFM images)) / 50. **(B)** Quantification of Aβ~42~ in human CSF samples in the presence of 10% glycerol by a spectrofluorimeter. A linear range of 0-1000 fM of Aβ~42~ and a detection limit of 143 fM were achieved. Error bars, standard deviation; n = 3.](thnov09p2939g004){#F3}

![Selectivity of the detection assay for Aβ~42~ and p-tau~181~ nanoprobes. The nanoprobes were incubated with 0 fM of the target protein, 500 fM of similar protein and a mixture of 500 fM of each protein from the protein pairs. Error bars, standard error of mean; n = 3. Corrected average net intensity = average net intensity of the sample - average net intensity of the probe. Average net intensity = ((1×1 square pixel of 50 individual MNCs) - (1×1 square pixel of 50 individual background area on the TIRFM images)) / 50.](thnov09p2939g005){#F4}

![Quantification of **(A)** Aβ~42~, **(B)** tau~441~ and **(C)** p-tau~181~ in human CSF samples using the developed assay (left) and a commercially available ELISA kit (right). Error bars, standard error of mean; n = 3. Average net intensity = ((1×1 square pixel of 50 individual MNCs) - (1×1 square pixel of 50 individual background area on the TIRFM images)) / 50.](thnov09p2939g006){#F5}

![**(A)** Schematic illustration of the detection assay for the simultaneous quantification of Aβ~42~ and tau~441~. Scale bar of the TIRFM image = 10 µm. SEM image of the magnetic Janus rods; scale bar = 5 µm. Calibration curves for the quantification of **(B)** monomeric Aβ~42~ and **(C)** tau~441~ using SPOH. The nanoprobes were incubated simultaneously with different concentrations of target, corresponding aptamer probes, amplification probes and SPOH. Error bars, standard error of mean; n = 3. Average net intensity for Aβ~42~ = ((1×10 square pixels of 50 individual MNCs) - (1×10 square pixels of 50 individual background areas on the TIRFM images)) / 50. Average net intensity for tau~441~ = ((1×1 square pixel of 50 individual MNCs) - (1×1 square pixel of 50 individual background areas on the TIRFM images)) / 50.](thnov09p2939g007){#F6}

###### 

Concentrations of 3 biomarkers in two types of biological fluids from 3 donors as determined by TIRFM.

  CSF samples                                                   
  --------------- ------------------- ------------------------- ----------------------
                  AD patient \#8075   Healthy donor \#7090093   Healthy donor \#8523
  Aβ42            553±8.4             741±14.3                  245±0.3
  tau441          312±0.4             241±1.1                   143±0.4
  p-tau181        74±1.5              53±0.5                    35±0.6
  Serum samples                                                 
                  AD patient \#8075   Healthy donor \#7090093   Healthy donor \#8523
  Aβ42            230±3.0             262±2.2                   133±1.3
  tau441          103±0.6             106±0.2                   569±15.0
  p-tau181        26±0.4              34±0.4                    90±1.5
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